Literature DB >> 22128115

Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?

Muhammad Adnan Khattak1.   

Abstract

Oxaliplatin-based chemotherapy regimens are the current standard treatment in the management of colorectal cancer. Neurotoxicity is the major cause of treatment delay, dose reduction, and cessation of oxaliplatin. Evidence regarding the role of calcium and magnesium prophylaxis to prevent oxaliplatin-related neurotoxicity is conflicting and further randomized data are needed to answer this question accurately. The purpose of this paper is to provide a critical overview of various studies that have been conducted so far to evaluate the preventative role of calcium and magnesium prophylaxis against oxaliplatin-related neurotoxicity.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22128115      PMCID： PMC3248777          DOI： 10.1634/theoncologist.2011-0157

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  21 in total

1.  Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

Authors:  Axel Grothey; Daniel A Nikcevich; Jeff A Sloan; John W Kugler; Peter T Silberstein; Todor Dentchev; Donald B Wender; Paul J Novotny; Umesh Chitaley; Steven R Alberts; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy.

Authors:  Laurence Gamelin; Michèle Boisdron-Celle; Alain Morel; Anne Lise Poirier; Virginie Berger; Erick Gamelin; Christophe Tournigand; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

3.  Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies.

Authors:  R K Ramanathan; M L Rothenberg; A de Gramont; C Tournigand; R M Goldberg; S Gupta; T André
Journal:  Ann Oncol       Date:  2009-11-03       Impact factor: 32.976

4.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Authors:  S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

5.  Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.

Authors:  Wen-Yee Chay; Sze-Huey Tan; Yew-Long Lo; Simon Yew-Kwang Ong; Hui-Cheng Ng; Fei Gao; Wen-Hsin Koo; Su-Pin Choo
Journal:  Asia Pac J Clin Oncol       Date:  2010-12       Impact factor: 2.601

6.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.

Authors:  Susanna B Park; Cindy S Y Lin; Arun V Krishnan; David Goldstein; Michael L Friedlander; Matthew C Kiernan
Journal:  Oncologist       Date:  2011-04-08

8.  The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.

Authors:  N Knijn; J Tol; M Koopman; M J B P Werter; A L T Imholz; F A A Valster; L Mol; A D Vincent; S Teerenstra; C J A Punt
Journal:  Eur J Cancer       Date:  2010-11-08       Impact factor: 9.162

9.  Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study.

Authors:  Keiichiro Ishibashi; Norimichi Okada; Tatsuya Miyazaki; Motohiko Sano; Hideyuki Ishida
Journal:  Int J Clin Oncol       Date:  2010-01-29       Impact factor: 3.402

10.  Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs.

Authors:  D Screnci; M J McKeage; P Galettis; T W Hambley; B D Palmer; B C Baguley
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640
View more
  10 in total

1.  Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity?

Authors:  Guido Cavaletti
Journal:  Oncologist       Date:  2011-11-29

2.  A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.

Authors:  Sina Vatandoust; Rohit Joshi; Kenneth B Pittman; Adrian Esterman; Vy Broadbridge; Jacqueline Adams; Nimit Singhal; Susan Yeend; Timothy Jay Price
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

Review 3.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

Review 4.  Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review.

Authors:  Cloé Brami; Ting Bao; Gary Deng
Journal:  Crit Rev Oncol Hematol       Date:  2015-11-23       Impact factor: 6.312

5.  EXPRESS: Methylcobalamin ameliorates neuropathic pain induced by vincristine in rats: Effect on loss of peripheral nerve fibers and imbalance of cytokines in the spinal dorsal horn.

Authors:  Jing Xu; Wei Wang; Xiong-Xiong Zhong; Yiwei Feng; Xuhong Wei; Xian-Guo Liu
Journal:  Mol Pain       Date:  2016-06-15       Impact factor: 3.395

Review 6.  Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Hana Starobova; Irina Vetter
Journal:  Front Mol Neurosci       Date:  2017-05-31       Impact factor: 5.639

7.  Use of Half-Generation PAMAM Dendrimers (G0.5-G3.5) with Carboxylate End-Groups to Improve the DACHPtCl2 and 5-FU Efficacy as Anticancer Drugs.

Authors:  Cláudia Camacho; Helena Tomás; João Rodrigues
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

8.  Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: A meta-analysis.

Authors:  Rui Ao; Yu-Hui Wang; Rui-Wen Li; Zheng-Rong Wang
Journal:  Exp Ther Med       Date:  2012-08-22       Impact factor: 2.447

9.  Clinical study on the prevention of oxaliplatin-induced neurotoxicity with guilongtongluofang: results of a randomized, double-blind, placebo-controlled trial.

Authors:  Yunfang Liu; Guangying Zhu; Li Han; Jie Liu; Ting Ma; Huiming Yu
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-13       Impact factor: 2.629

Review 10.  The Rehabilitation of Oncological Patients Presenting Neuropathies.

Authors:  Elena Claudia Micu; Laszlo Irsay
Journal:  Clujul Med       Date:  2014-05-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.